About Clinical Research
Study #51023
This study will be evaluating the safety and tolerability of an investigational RSV vaccine in adults with chronic medical conditions of the heart, lungs, kidneys and/or liver.
Are You a Good Fit?
- Receive up to $420 for your participation in this study
What are the Time Requirements?
This study will consist of 1-screening/dosing, 1-outpatient visit and 1 follow-up telephone contact. Study dates are as follows:
Group 1
Visit DatesStay
Friday, May 12, 2023 - Friday, May 12, 2023
Return
Friday, June 9, 2023
Follow-up Phone Call
Friday, November 3, 2023
How Much: $420
BMI Calculator
Referral Program
Do not forget our REFERRAL PROGRAM. Earn at least $200 for every new participant you refer who completes a study.*
*No referral bonuses are paid out for outpatient vaccine studies.
All study dates are tentative and subject to change.
We will update the clinical research studies list weekly. Be sure to check with us either by calling or going online. Call (417) 831-2048 or visit 417studies.com more information. You can also visit the Screening and Recruitment Center located at 2025 W. Sunshine Street, L-109. Office hours are Monday through Friday from 8 a.m. to 5 p.m.
• Participants who are willing and able to comply with all scheduled visits, vaccination plan, lifestyle considerations, and other study procedures.
• Participants who are considered at high risk of RSV disease by virtue of the following:
– Adults with chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus).
– Chronic medical conditions for this study are defined as:
– Duration greater than 6 months.
– Stable disease not requiring a significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention.
– Requires regular medical follow-up or ongoing medication or hospitalization in the previous year.
• Participants who are considered at high risk of RSV disease by virtue of the following:
– Adults with chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus).
– Chronic medical conditions for this study are defined as:
– Duration greater than 6 months.
– Stable disease not requiring a significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention.
– Requires regular medical follow-up or ongoing medication or hospitalization in the previous year.
If you have previously submitted an application, call 417-831-2048 to enroll. Or click on the button below to submit your application now.